Global Search

Search articles, concepts, and chapters

Science translational medicineApril 20260 citations

Real-time intraocular pressure monitoring and responsive drug release in preclinical models by an all-polymer smart contact lens.

Cai, Yuting, Zhang, Chenguang, Dang, Pengrui, Liu, Chenshu, Du, Yuxuan, Haghniaz, Reihaneh, Wang, Jiechen, Khosravi, Safoora, Luo, Zhengtang, Servati, Peyman, Chen, Lili, Wolffsohn, James S, Lee, Tae-Woo, Zhu, Yangzhi


AI Summary

This smart contact lens monitors eye pressure and automatically releases glaucoma medication when pressure is high, offering a personalized, real-time treatment solution.

Abstract

Glaucoma remains a leading cause of irreversible blindness worldwide, yet conventional topical therapies are often hampered by poor patient adherence, and standard in-office applanation tonometry captures only static measurements, failing to capture the dynamic nature of intraocular pressure (IOP). Smart contact lenses have emerged as promising tools for home-based, real-time IOP monitoring and feedback-guided therapy; however, most rely on bulky or rigid electronics that impair comfort, safety, and visual performance. Here, we report a battery-free, all-polymer microfluidic theranostic smart contact lens (AP-TSCL) that enables autonomous IOP-responsive glaucoma therapy without bulky electronic components. The AP-TSCL integrates a noninvasive microfluidic IOP sensor with a multistage, pressure-gated drug delivery architecture. Embedded microchannels define distinct activation thresholds, enabling lens deformation under elevated IOP to drive staged release from multiple drug reservoirs. Across in vitro (artificial eye model), ex vivo (enucleated bovine eyes), and in vivo (rabbit ocular hypertension) studies, the device achieved tonometry-aligned IOP tracking, pressure-triggered delivery of timolol or brimonidine above preset thresholds, and IOP lowering comparable to conventional topical therapy. This preclinical evidence suggests that the fully integrated platform may overcome key limitations of existing technologies and offers a clinically translatable solution for personalized ocular care.


MeSH Terms

Intraocular PressureAnimalsContact LensesDrug LiberationPolymersRabbitsCattleTimololGlaucomaDrug Delivery SystemsHumansMonitoring, PhysiologicTonometry, Ocular

Key Concepts5

The all-polymer microfluidic theranostic smart contact lens (AP-TSCL) enabled autonomous intraocular pressure (IOP)-responsive glaucoma therapy without bulky electronic components in preclinical models.

TreatmentBasic SciencePreclinical studyn=Not specified (in vitro, ex vivo, in …Ch28Ch29

The all-polymer microfluidic theranostic smart contact lens (AP-TSCL) achieved tonometry-aligned intraocular pressure (IOP) tracking in in vitro (artificial eye model), ex vivo (enucleated bovine eyes), and in vivo (rabbit ocular hypertension) studies.

DiagnosisBasic SciencePreclinical studyn=Not specified (in vitro, ex vivo, in …Ch3

The all-polymer microfluidic theranostic smart contact lens (AP-TSCL) demonstrated pressure-triggered delivery of timolol or brimonidine above preset thresholds in in vitro (artificial eye model), ex vivo (enucleated bovine eyes), and in vivo (rabbit ocular hypertension) studies.

TreatmentBasic SciencePreclinical studyn=Not specified (in vitro, ex vivo, in …Ch29Ch30

The all-polymer microfluidic theranostic smart contact lens (AP-TSCL) achieved intraocular pressure (IOP) lowering comparable to conventional topical therapy in in vitro (artificial eye model), ex vivo (enucleated bovine eyes), and in vivo (rabbit ocular hypertension) studies.

Comparative EffectivenessBasic SciencePreclinical studyn=Not specified (in vitro, ex vivo, in …Ch28Ch29

The all-polymer microfluidic theranostic smart contact lens (AP-TSCL) integrated a noninvasive microfluidic IOP sensor with a multistage, pressure-gated drug delivery architecture.

MechanismBasic SciencePreclinical studyn=Not specified (in vitro, ex vivo, in …Ch2Ch3

Is this article assigned to the wrong chapter(s)? Let us know.